Latest studies
- RecruitingPHASE3
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
This study is looking at a new medicine called AZ-3102 for children and young people with rare conditions like Niemann-Pick Type C, GM1 Gangliosidosis, or GM2 Gangliosidosis. It aims to see if the medicine is safe and if it helps improve their health over 18 months.
Niemann-Pick Type C DiseaseGM1 GangliosidosisGM2 GangliosidosisAustralia - RecruitingPHASE3
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
This study is looking at the safety of a new patch treatment, called Viaskin Peanut Patch (DBV712), for peanut allergy in very young children (1 to 3 years old). It aims to see if the patch is safe over six months, with some children receiving the patch and others a dummy patch.
AllergyPeanut AllergyAustralia - Active not recruitingPHASE2
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
This study looks at a new treatment called patritumab deruxtecan for people with an advanced type of lung cancer that has a specific genetic change (EGFR mutation). It's for those who have already tried other standard treatments that are no longer working.
Non-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorAustralia - Active not recruitingPHASE3
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
This study compares two treatments, abatacept and adalimumab, for adults with early, severe rheumatoid arthritis who haven't responded well to methotrexate. It aims to see which treatment is better at reducing arthritis symptoms and improving quality of life.
Rheumatoid ArthritisAustralia - Active not recruitingPHASE3
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
This study is looking at a new medicine called Olezarsen for people with very high triglyceride levels. It's an ongoing study for those who have already started the treatment in previous trials, checking its long-term safety and how well it's tolerated.
Severe HypertriglyceridemiaAustralia - Active not recruitingPHASE3
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This study is looking into a new medication called lanifibranor for adults with a liver condition called NASH (Nonalcoholic Steatohepatitis) and significant liver scarring (fibrosis F2 or F3). Researchers want to see if it's safe and helps improve the liver condition.
NASH - Nonalcoholic SteatohepatitisAustralia - RecruitingPHASE1, PHASE2
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
This study is testing a new treatment, EP-104GI, for adults with eosinophilic esophagitis (EoE). It aims to see if it's safe, how well it works, and how the body handles it. Participants will either receive the treatment or a dummy version.
Eosinophilic EsophagitisAustralia - Active not recruitingPHASE3
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study is looking at how a medication called Tirzepatide might help people living with obesity. Researchers want to see if it can reduce serious health problems and improve overall health in adults.
ObesityOverweightAustralia - Enrolling by invitationPHASE3
Long-term Extension of GTX-102 in Angelman Syndrome
This study is looking into the long-term safety and effects of a treatment called GTX-102 for people with Angelman Syndrome. It's for those who have already been in an earlier study with this treatment.
Angelman SyndromeAustralia - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerAustralia - Active not recruitingPHASE2
Atrasentan in Patients With Proteinuric Glomerular Diseases
This study looks at a new medicine called atrasentan for people with certain kidney diseases. It aims to see if atrasentan can help reduce protein in the urine and protect kidney function. Different groups of patients with kidney conditions like IgA nephropathy and diabetic kidney disease are being included.
IgA NephropathyFocal Segmental GlomerulosclerosisAlport SyndromeDiabetic Kidney DiseaseAustralia - Active not recruitingPHASE3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
This study looks at a new drug, imlunestrant, for early breast cancer. It compares it to standard hormone treatments like tamoxifen, anastrozole, letrozole, and exemestane. The goal is to see if imlunestrant works better for patients whose cancer is at higher risk of returning.
Breast NeoplasmsAustralia - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVAustralia - RecruitingPHASE1, PHASE2
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
This study is looking for new ways to treat specific childhood cancers that have come back or not responded to previous treatments. It investigates a new medicine called HER3-DXd (also known as patritumab deruxtecan) for safety and effectiveness in children aged 1 month to 17 years with hepatoblastoma or rhabdomyosarcoma.
Malignant NeoplasmAustralia - Active not recruitingPHASE2, PHASE3
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
This study is looking at a new treatment for advanced head and neck cancer. It combines two medicines, INBRX-106 and pembrolizumab, to see if they work better together than pembrolizumab alone. It's for people whose cancer can't be cured by other methods.
Head and Neck Squamous Cell Carcinoma (HNSCC)Australia - Enrolling by invitationPHASE3
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
This study looks at the long-term safety of a medicine called eplontersen for adults with a heart condition called ATTR-CM. It's for people who have already taken part in a related study to see how the treatment works over a longer time.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)Australia - Active not recruitingPHASE3
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
This study looks at new treatments for a type of oesophageal cancer that hasn't spread after initial therapy. It tests two new medicines, tiragolumab and atezolizumab, to see if they can help stop the cancer from coming back or getting worse.
Esophageal Squamous Cell CarcinomaAustralia - RecruitingNA
Physical Exercise During Preoperative Chemotherapy for Breast Cancer
This study looks at whether regular exercise during chemotherapy for breast cancer can help the treatment work better. It aims to see if exercise helps clear the cancer completely and if it improves patients' well-being during treatment and recovery.
Breast CancerAustralia - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
Advanced Non-small Cell Lung CancerHER2 MutationAustralia - RecruitingPHASE3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
This study is testing a new medicine, glofitamab, for people in the UK with a type of blood cancer called mantle cell lymphoma. It aims to see if glofitamab works better than standard treatments for those whose cancer has returned or isn't responding to past therapies.
LymphomaAustralia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
This study is testing a new medicine, CAEL-101, for people with a serious heart condition called AL amyloidosis. Researchers want to see if it helps people live longer, reduces hospital stays, and is safe when added to standard treatment.
AL AmyloidosisAustralia - Active not recruitingPHASE3
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
This study looks at new drug combinations for a type of lung cancer called Limited-Stage Small Cell Lung Cancer (LS-SCLC). Researchers want to see if adding pembrolizumab and olaparib to standard treatments helps people live longer.
Small Cell Lung CancerAustralia - RecruitingPHASE2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
This study is a research programme looking at new ways to treat cancer in children and young adults aged 1 to 39. It tests different medicines to find out how well they work and if they are safe.
NeoplasmsChildAdolescentAustralia - Active not recruitingPHASE2
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
This study is testing a new combination of treatments, Intismeran autogene and Pembrolizumab, for kidney cancer. We want to see if this combination, given after surgery, can help stop the cancer from coming back for longer compared to Pembrolizumab alone.
Renal Cell CarcinomaAustralia - Active not recruitingPHASE4
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
This study compares two treatments, Radium-223 (Xofigo) and ARPI therapy, for prostate cancer that has spread to the bones. It aims to see which is more effective and safer for men who have already tried ARPIs.
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Australia - Active not recruitingPHASE3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
This study looks at a new drug, isatuximab, combined with standard treatments (lenalidomide and dexamethasone) for people with high-risk smoldering multiple myeloma. It aims to see if this combination can prevent the disease from getting worse compared to the standard treatments alone.
Plasma Cell MyelomaAustralia - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
This study is testing a new combination treatment for bladder cancer that hasn't spread. It combines standard chemotherapy and radiotherapy with a new drug called pembrolizumab, which helps your immune system fight cancer. We want to see if this new combination works better.
Urinary Bladder NeoplasmsAustralia - Active not recruitingPHASE1, PHASE2
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
This study is testing a new medicine called epcoritamab, sometimes with other treatments, for people with B-cell non-Hodgkin lymphoma. Doctors want to check if it's safe and if it helps shrink the cancer. It's given by injection under the skin.
Diffuse Large B-Cell LymphomaFollicular LymphomaAustralia - Enrolling by invitationPHASE2, PHASE3
An Interventional Study of Infigratinib in Children With Hypochondroplasia
This study is looking at a new medicine called infigratinib for children with hypochondroplasia (a type of short stature). It's checking if the medicine is safe and helps children grow better. Children aged 3 to 18 might be able to take part.
HypochondroplasiaAustralia - Recruiting
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
The MOMENTUM Study is tracking how a new type of advanced radiotherapy, called MR-Linac, works for people with different cancers. It aims to see if this treatment improves survival, controls cancer better, and enhances quality of life by using highly precise radiation guidance.
OncologyBreast CancerProstate CancerGynecologic CancerAustralia - RecruitingPHASE3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
This study is looking into a new drug, AZD5335, for women with advanced ovarian cancer that has become resistant to usual chemotherapy. It compares AZD5335 to existing treatments to see if it works better at controlling the cancer's growth.
Epithelial Ovarian CancerAustralia - RecruitingNA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
This study looks at a new way to fix shoulder tendons that are partly torn. It compares a special implant called REGENETEN™ to a standard repair, to see if the implant helps people get back to daily activities faster.
Rotator Cuff InjuriesAustralia - Active not recruitingPHASE1, PHASE2
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
This study is testing a new medicine called brenetafusp for people with certain advanced solid cancers that haven't responded to other treatments. It checks how safe and effective brenetafusp is, both alone and with other common cancer drugs.
Select Advanced Solid TumorsAustralia - Active not recruitingPHASE2
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
This study is looking into a new medication called VHB937 for people with early-stage ALS. We want to see if it's safe and helps improve daily activities and breathing, compared to a dummy drug (placebo).
Amyotrophic Lateral Sclerosis (ALS)Australia - RecruitingPHASE3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
This study compares a new medication, Bomedemstat, with a standard treatment, Hydroxyurea, for people with Essential Thrombocythemia (ET). It wants to see if Bomedemstat works better at controlling ET for those new to treatment.
Essential ThrombocythemiaAustralia - RecruitingPHASE1, PHASE2
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
This study is testing a new drug, BAY 3713372, for certain solid tumours that are missing a specific gene (MTAP-deleted). It aims to find a safe dose, understand how it works in the body, and see if it can shrink these tumours.
MTAP-deleted Solid TumorsAustralia - Recruiting
International Study of Cerebral Oxygenation and Electrical Activity During Major Neonatal Surgery
This study looks at how much oxygen babies' brains get during major surgery for birth defects. Researchers use special monitors to see if low oxygen levels are linked to how well babies recover after their operation.
Congenital DisordersCerebral DesaturationNeonatal SurgeryAustralia - Active not recruitingPHASE3
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
This study looks at a new immune-boosting medicine called Nivolumab for people who have had surgery for bladder or kidney drainage system cancer. It compares Nivolumab to a dummy drug to see if it's safe and helps stop the cancer from coming back.
Various Advanced CancerAustralia - Active not recruitingPHASE2
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
This study looks at a new drug, evorpacept, combined with an existing one, pembrolizumab, for advanced head and neck cancer. It aims to see if this combination works better than pembrolizumab alone for patients who haven't had treatment for advanced stages of their cancer. It's a Phase 2 trial, meaning it's still in earlier stages of testing.
Head and Neck CancerHead and Neck Squamous Cell CarcinomaAustralia - Active not recruitingPHASE3
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
This study looks at a drug called Olaparib for people in the UK with a specific type of breast cancer linked to a BRCA gene change. It aims to see if Olaparib, given after standard treatments, can help prevent the cancer from coming back.
Breast CancerAustralia - RecruitingPHASE2
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
This study explores a new treatment for aggressive bladder cancer that hasn't spread to the muscle. Researchers are testing if adding a new drug, intismeran autogene, to standard treatment (BCG) helps patients live longer without their cancer growing or returning. It's for adults with high-risk non-muscle invasive bladder cancer.
Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder NeoplasmsCarcinoma in SituAustralia - RecruitingPHASE2
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
This study looks at a new treatment called LN-145 for advanced lung cancer (non-small cell type) that has spread. It involves using your own immune cells to fight the cancer. Researchers want to see how safe and effective this treatment is.
Metastatic Non Small Cell Lung CancerAustralia - Active not recruitingPHASE3
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
This study is testing a new drug, AZD9833, for advanced breast cancer. It's for people whose cancer has a specific gene change (ESR1 mutation) and are already on certain treatments. Researchers want to see if adding AZD9833 works better than current medicines.
ER-Positive HER2-Negative Breast CancerAustralia - Active not recruitingPHASE4
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
This study is looking at a new treatment called guselkumab for people with psoriatic arthritis that affects the spine and pelvis. It aims to see how well it reduces pain and inflammation in these areas. Participants will receive either the study drug or a dummy treatment.
Arthritis, PsoriaticAustralia - Active not recruitingPHASE2
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
This study is testing a new medicine, bezuclastinib, for people with certain types of mastocytosis (a rare blood disorder). It compares bezuclastinib with a dummy pill (placebo) to see if it safely helps reduce symptoms that aren't well controlled by current treatments.
SSMMastocytosis, IndolentMastocytosis, SystemicMastocytosisAustralia - RecruitingPHASE1, PHASE2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
This study is looking at a new medicine called ETX101 for babies and children with Dravet Syndrome. Researchers want to see if it's safe and helps reduce seizures. It includes different age groups, from 6 months up to 17 years.
Dravet SyndromeAustralia - Not yet recruitingPHASE3
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
This study for advanced neuroendocrine cancer compares a new drug called obrixtamig with standard chemotherapy. It aims to see if adding obrixtamig helps people live longer and also tests a new device to measure a cancer marker.
Extrapulmonary Neuroendocrine CancerAustralia - RecruitingPHASE3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
This study is testing a new medicine, enlicitide, for high cholesterol. Researchers want to see if combining enlicitide with a common cholesterol medicine, rosuvastatin, works better at lowering 'bad' cholesterol than rosuvastatin alone. It's for adults aged 18-64.
HyperlipidemiaAustralia - RecruitingPHASE3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study looks into a new treatment for adults with heart failure. It combines two medicines, vicadrostat and empagliflozin, to see if they can improve heart health in people with a specific type of heart failure. Participants take tablets daily and are closely monitored.
Heart FailureAustralia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
This study is testing a new medicine called sefaxersen for people with a kidney disease called IgA nephropathy. We want to see if it's safe and helps slow down kidney damage, especially for those at higher risk.
Primary IgA NephropathyAustralia